A Trial to Examine if Repinatrabit is Processed Differently in Adults With Reduced Liver or Kidney Function Compared to Adults With Normal Liver and Kidney Function

Sponsor ID
359-201-00009
Clinicaltrials.gov ID
NCT07713758
EudraCT ID
N/A
EUCTIS ID
N/A
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Study Contact Information
844-687-8522 or [email protected]
Recruiting
Sponsor ID
359-201-00009
Trial Details
Subscribe for updates
Age
18 - 65 Years
Therapeutic Area
  • Phenylketonuria (PKU)
    • Sex
    Female & Male
    Trial Dates
    Jul 2026 - Feb 2027
    Healthy Volunteers
    Yes
    • Body mass index (BMI) from 18.0 to 38.0 kilograms per square meter (kg/m\^2) (inclusive).
    • Able to provide written, informed consent.
    • Male participants and female participants of childbearing potential (POCBP) must agree to remain fully abstinent from intercourse where pregnancy can occur OR practice 2 different contraceptive methods, where at least one must be highly effective.
    • Otherwise be in generally good health.
    • Additional criteria for Group 1:
    • i. Have moderate hepatic impairment determined using Child-Pugh classification (Class B).
    • ii. Have relatively stable hepatic function for the duration of the study as determined by the investigator and liver function test at the time of screening or stable hepatic function 1 year prior to screening.
    • iii. Have normal renal function. iv. Have a clinical diagnosis of hepatic cirrhosis based on biopsy and/or clinical criteria.
    • Additional criteria for Group 2:
    • i. Have estimated glomerular filtration rate based on the Chronic Kidney Disease-Epidemiology Collaboration (eGFRCKD-EPI) lesser than (\<) 30 milliliters per minute per 1.73 square meters (mL/min/1.73 m\^2) indicating severe renal impairment.
    • ii. Not currently be on dialysis. iii. Have relatively stable renal function as determined by eGFRCKD-EPI. 7) Additional criteria for Group 3: i. eGFRCKD-EPI greater than or equal to (≥) 90 mL/min/1.73 m\^2 indicating normal renal function.
    • ii. Have liver enzymes within normal limits.
    • Participants who are breastfeeding.
    • Participants who have a positive pregnancy test result prior to receiving the investigational medical product (IMP).
    • Participants with international normalized ratio (INR) greater than (\>) 2.3. Participants with hepatic impairment with elevated INR will be excluded based on the investigator's discretion.
    • Participants with hepatic carcinoma or porto-hepatic shunts that have been surgically created or planted.
    • A history of difficulty in obtaining intravenous access.
    • The donation of blood or plasma \> 250 milliliters (mL) within 30 days prior to screening or received \> 50 mL of blood or plasma within 30 days prior to screening.
    • Participants who have taken an investigational drug within 30 days prior to screening.
    • Exposure to any substances known to stimulate hepatic microsomal enzymes within 30 days prior to screening (eg, occupational exposure to pesticides, organic solvents, etc).
    • Any participant who, in the opinion of the investigator, should not participate in the trial.
    • Previous exposure to repinatrabit.
    • Additional criteria for Group 1: History of serious mental disorder including participants who have greater than Grade 1 encephalopathy as assessed by the Child-Pugh score and/or the investigator's judgment.
    • Additional criteria for Group 2:
    • i) Participants that have undergone a renal transplant. ii) Participants expected to require dialysis within 45 days. iii) Clinically significant abnormal findings in the serum chemistry, hematology, or urinalysis results obtained at screening or on Day -1, other than those associated with underlying renal conditions and other stable medical conditions consistent with the disease processes.
    • Additional criteria for Group 3: History of or current hepatitis, or carriers of hepatitis B surface antigen (HBsAg) and/or hepatitis C antibodies (anti-HC).
    • Note: Other protocol-specified inclusion/exclusion criteria may apply.

    Study Summary

    This trial is intended to understand how the body processes repinatrabit in people with moderate liver impairment and severe kidney impairment and also to compare these results with people of similar age, weight, and sex who have normal liver function.

    Additional Study Details

    Phase
    Phase 1
    Study Drug
    Drug: Repinatrabit
    Type
    Interventional
    Masking
    None (Open Label)
    Estimated Enrollment
    32
    Additional Study Details

    Inclusion and Exclusion Criteria

    Inclusion Criteria

    • 1. Body mass index (BMI) from 18.0 to 38.0 kilograms per square meter (kg/m\^2) (inclusive).
    • 2. Able to provide written, informed consent.

    Exclusion Criteria

    • 1. Participants who are breastfeeding.
    • 2. Participants who have a positive pregnancy test result prior to receiving the investigational medical product (IMP).
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    • Body mass index (BMI) from 18.0 to 38.0 kilograms per square meter (kg/m\^2) (inclusive).
    • Able to provide written, informed consent.
    • Male participants and female participants of childbearing potential (POCBP) must agree to remain fully abstinent from intercourse where pregnancy can occur OR practice 2 different contraceptive methods, where at least one must be highly effective.
    • Otherwise be in generally good health.
    • Additional criteria for Group 1:
    • i. Have moderate hepatic impairment determined using Child-Pugh classification (Class B).
    • ii. Have relatively stable hepatic function for the duration of the study as determined by the investigator and liver function test at the time of screening or stable hepatic function 1 year prior to screening.
    • iii. Have normal renal function. iv. Have a clinical diagnosis of hepatic cirrhosis based on biopsy and/or clinical criteria.
    • Additional criteria for Group 2:
    • i. Have estimated glomerular filtration rate based on the Chronic Kidney Disease-Epidemiology Collaboration (eGFRCKD-EPI) lesser than (\<) 30 milliliters per minute per 1.73 square meters (mL/min/1.73 m\^2) indicating severe renal impairment.
    • ii. Not currently be on dialysis. iii. Have relatively stable renal function as determined by eGFRCKD-EPI. 7) Additional criteria for Group 3: i. eGFRCKD-EPI greater than or equal to (≥) 90 mL/min/1.73 m\^2 indicating normal renal function.
    • ii. Have liver enzymes within normal limits.
    Exclusion Criteria:
    • Participants who are breastfeeding.
    • Participants who have a positive pregnancy test result prior to receiving the investigational medical product (IMP).
    • Participants with international normalized ratio (INR) greater than (\>) 2.3. Participants with hepatic impairment with elevated INR will be excluded based on the investigator's discretion.
    • Participants with hepatic carcinoma or porto-hepatic shunts that have been surgically created or planted.
    • A history of difficulty in obtaining intravenous access.
    • The donation of blood or plasma \> 250 milliliters (mL) within 30 days prior to screening or received \> 50 mL of blood or plasma within 30 days prior to screening.
    • Participants who have taken an investigational drug within 30 days prior to screening.
    • Exposure to any substances known to stimulate hepatic microsomal enzymes within 30 days prior to screening (eg, occupational exposure to pesticides, organic solvents, etc).
    • Any participant who, in the opinion of the investigator, should not participate in the trial.
    • Previous exposure to repinatrabit.
    • Additional criteria for Group 1: History of serious mental disorder including participants who have greater than Grade 1 encephalopathy as assessed by the Child-Pugh score and/or the investigator's judgment.
    • Additional criteria for Group 2:
    • i) Participants that have undergone a renal transplant. ii) Participants expected to require dialysis within 45 days. iii) Clinically significant abnormal findings in the serum chemistry, hematology, or urinalysis results obtained at screening or on Day -1, other than those associated with underlying renal conditions and other stable medical conditions consistent with the disease processes.
    • Additional criteria for Group 3: History of or current hepatitis, or carriers of hepatitis B surface antigen (HBsAg) and/or hepatitis C antibodies (anti-HC).
    • Note: Other protocol-specified inclusion/exclusion criteria may apply.

    Locations

    Location
    Status
    Location
    Panax Clinical Research
    Miami, Florida, United States, 33014
    Status
    Recruiting

    © 2026 Otsuka America Pharmaceutical, Inc.

    All rights reserved.

    January 2026 01US25EUC0489

    We defy limitation,

    so that others can too.

    Follow Us
    OAPI and OPDC Locations

    508 Carnegie Center Dr,

    Princeton, NJ 08540, United States

    Phone +1 609-524-6788

    2440 Research Blvd,

    Rockville, MD 20850, United States

    Phone +1 301-424-9055

    3956 Point Eden Way

    Hayward, CA 94545, United States

    Phone +1 800-562-3974